EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study

Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang, Hsuan-Yuan Chang, Yu-Min Lin

Frontiers in Pharmacology · 31.07.2026 · 17

DOI: 10.3389/fphar.2026.1877392 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.07.2026. Verfasst von Jheng-Yan Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sepsis-induced cardiomyopathy (SICM) is an important cardiovascular complication of infection and sepsis, particularly in patients with type 2 diabetes mellitus (T2DM). Whether antecedent glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower SICM risk remains unclear.

Methods

We conducted a retrospective active-comparator cohort study using the TriNetX United States federated electronic health record network from 1 January 2010, to 30 November 2025. Adults with T2DM and documented infection were classified according to antecedent GLP-1 RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) exposure before the index infection date and matched 1:1 by propensity score. The primary outcome was 1-year EHR-ascertained SICM or SICM-related cardiac dysfunction, defined using diagnostic codes for acute pulmonary edema, heart failure, cardiogenic shock, or cardiomyopathy, or objective cardiac dysfunction.

Results

Among 189,156 eligible patients, propensity-score matching yielded 62,267 patients in each group. Over 1 year, EHR-ascertained SICM or SICM-related cardiac dysfunction occurred in 2,503 patients (4.0%) in the GLP-1 RA group and 3,059 patients (4.9%) in the DPP-4i group (HR 0.82, 95% CI 0.78–0.87; P < 0.001; E-value 1.7). GLP-1 RA use was also associated with lower risks of surrogate cardiac dysfunction (HR 0.70, 95% CI 0.64–0.76), systolic SICM (HR 0.85, 95% CI 0.77–0.93), diastolic SICM (HR 0.88, 95% CI 0.81–0.95), hyperdynamic SICM (HR 0.82, 95% CI 0.71–0.95), new-onset heart failure (HR 0.85, 95% CI 0.80–0.89), and all-cause mortality (HR 0.64, 95% CI 0.60–0.68), but not right ventricular dysfunction SICM. Negative control outcomes showed null associations, and landmark analyses were consistent.

Conclusion

In this United States real-world active-comparator cohort study, antecedent GLP-1 RA exposure was associated with a lower 1-year risk of EHR-ascertained SICM or SICM-related cardiac dysfunction compared with antecedent DPP-4i exposure. These findings were consistent across sensitivity analyses and support further prospective investigation into the relationship between antecedent GLP-1 RA exposure and cardiovascular vulnerability after infection.

Schlagwörter

Stichwörter der Autor:innen

dipeptidyl peptidase-4 inhibitorglucagon-like peptide-1 receptor agonistreal-world evidencesepsis-induced cardiomyopathytype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chi Mei Hospital, Chiali, Tainan, Taiwan.
  • Department of Medical Education, Chi Mei Medical Center, Tainan, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Chi Mei Medical Centre, Tainan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.

Zitieren

APA

Wu, J. Y., Lee, K. W., Huang, S. C., Chang, H. Y., & Lin, Y. M. (2026). Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1877392

Vancouver

Wu JY, Lee KW, Huang SC, Chang HY, Lin YM. Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1877392

BibTeX
@article{Wu2026,
  author = {Wu, Jheng-Yan and Lee, Keng-Wei and Huang, Sheng-Chi and Chang, Hsuan-Yuan and Lin, Yu-Min},
  title = {Antecedent glucagon-like peptide-1 receptor agonist use and risk of sepsis-induced cardiomyopathy in type 2 diabetes: a United States real-world active-comparator cohort study},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1877392}
}
Kostenlos starten →